AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Myomo® Announces New Distribution Agreement for Australia / New Zealand

May 1, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2019--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with NeuroMuscular Orthotics Pty Ltd (NMO) with the goal of offering MyoPro across Australia and New Zealand.

NMO is the leading Australian specialist in facilitating optimal orthotic care of individuals with long term functional impairment as a result of neurological and orthopedic pathologies. The company achieves this through direct clinical service provision to its own clients in Melbourne and Sydney, and through its sister clinic Interface Orthotics in Perth. In addition, NeuroMuscular Orthotics expands its reach throughout Australia and New Zealand by offering distribution, central fabrication and education to certified orthotist/prosthetists.

Darren Pereira, NMO Director, explains, “NeuroMuscular Orthotics is excited to be partnering with the passionate and innovative team at Myomo to bring the MyoPro powered orthosis to Australia and New Zealand. As the only product of its kind, the MyoPro will unlock new possibilities for many Australians and New Zealanders with upper limb impairment, aiding in their social and economic participation, helping them to achieve their goals and live an ordinary life.”

Myomo and NMO launched MyoPro across Australia with a comprehensive joint roadshow, visiting Brisbane, Melbourne, Adelaide, Perth, Sydney and Gold Coast. Together, the team trained 25 orthotics and prosthetics clinicians, evaluated 30 potential MyoPro patients and trained allied rehabilitation physicians, physiotherapists and occupational therapists.

Paul R. Gudonis, Chairman and CEO of Myomo, said, “NMO is one of the strongest technical orthotics providers in one of the strongest economies in the Pacific region. It is an honor to call them a partner, and we look forward to offering MyoPro to the tens of thousands of Australians suffering a paralyzed arm from stroke, nerve injury of other neuromuscular disease.”

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, our collaboration with NeuroMuscular Orthotics and plans for offering our MyoPro product in Australia and New Zealand. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Our actual results could differ materially from those anticipated in these forward looking statements for many reasons, including, without limitation, risks related to regulatory approval and market acceptance of our products, our ability to secure and maintain reimbursement for our products, our ability to obtain additional funding to sustain and grow our business, and the other risk factors contained in our filings made with the Securities and Exchange Commission. More information about factors that potentially could affect Myomo’s business and financial results is included in Myomo’s filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190501005064/en/

CONTACT: Investor Relations:

Vivian Cervantes

PCG Advisory

646-863-6274

vivian@pcgadvisory.com

Public Relations:

Sarah Karr

Matter Communications

978-518-4817

myomo@matternow.com

KEYWORD: AUSTRALIA UNITED STATES NORTH AMERICA AUSTRALIA/OCEANIA NEW ZEALAND MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES GENERAL HEALTH PHYSICAL THERAPY

SOURCE: Myomo, Inc.

Copyright Business Wire 2019.

PUB: 05/01/2019 08:00 AM/DISC: 05/01/2019 08:01 AM

http://www.businesswire.com/news/home/20190501005064/en